Veracyte vs GeneDx
VCYT and WGS side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How VCYT and WGS compare
Veracyte is the larger company, worth 1.3 times as much as GeneDx ($1.9B against $1.5B).
GeneDx grew revenue faster over the last twelve months (25.4% versus 17.3% for Veracyte).
Veracyte keeps more of each dollar of sales as profit, with a net margin of 20.4% compared with −23.4% at GeneDx.
Veracyte scores higher on the StockData Score (16 against 6 for GeneDx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | VCYT | WGS |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $1.5B |
| Share price | $24.23 | $51.02 |
| Change, 1 year | −38.4% | −60.9% |
| Change, 5 years | −41.7% | −77.6% |
| Beta (5Y) | 1.92 | 0.82 |
| Employees | 755 | 1,300 |
| StockData Score | ||
| Total score | 16 (better) | 6 |
| Valuation score | 4 (better) | 0 |
| Growth score | 3 | 3 |
| Performance score | 3 (better) | 1 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 17.3× | – |
| P/S | 3.5× | 3.3× (better) |
| P/B | 1.4× (better) | 6.2× |
| EV/EBITDA | 13.0× | – |
| P/FCF | 11.7× | – |
| FCF yield | 8.5% (better) | −5.0% |
| Fair value | $36.51 | $32.23 |
| Margin of safety | 33.6% (better) | −58.3% |
| Growth | ||
| Revenue growth (TTM) | 17.3% | 25.4% (better) |
| Revenue growth, 5Y average | 34.5% (better) | 19.0% |
| Net income growth (TTM) | 335% (better) | −7665% |
| EPS growth (TTM) | 324% (better) | −18300% |
| Profitability | ||
| Gross margin | 71.7% (better) | 69.4% |
| Operating margin | 18.8% (better) | −20.3% |
| Net margin | 20.4% (better) | −23.4% |
| FCF margin | 29.5% (better) | −16.7% |
| Return on equity | 8.8% (better) | −40.8% |
| Return on invested capital | 10.0% (better) | −36.2% |
| Financial health | ||
| Debt / equity | 0.00 | 0.40 (better) |
| Current ratio | 9.16 (better) | 3.30 |
| Altman Z-score | 12.65 (better) | 0.36 |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 111% | 107% |
| Held by insiders | 1.7% | – |
| Insider net buying, 12 months | −$18.6M | $91.2M (better) |
| Short interest, % of float | 12.1% | – |
Go deeper
- VCYT stock overview
- VCYT income statement
- VCYT valuation and score
- WGS stock overview
- WGS income statement
- WGS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.